Biopharma Executives Concerned as FDA’s Peter Marks, Overseer of Vaccines and Gene Therapies, Departs

Biopharmaceutical executives are expressing concern regarding the recent departure of Peter Marks from his role at the Food and Drug Administration (FDA). Marks previously held responsibility for overseeing critical areas, including vaccines, gene therapies, and the nation’s blood supply. Marks’ oversight at the FDA included the regulation and safety of vaccines, a field of heightened public interest. His role also encompassed gene therapies, an area of rapidly advancing medical innovation. Furthermore, Marks was responsible for maintaining the safety and integrity of the blood supply, a vital component of the healthcare system. The biopharma industry now watches how the FDA will proceed without his guidance in these important sectors.

Newsflash | Powered by GeneOnline AI
Source: https://www.statnews.com/pharmalot/2025/03/31/who-jnj-fda-marks-amgen-colorado-medicines-pharma-montana-pharmacies-nih-europe/?utm_campaign=rss Mon, 31 Mar 2025 13:22:14 +0000

Related posts:

DrugPatentWatch: Generic Drug Development Accelerated Through Partnerships DrugPatentWatch Highlights API Data as Foundation for Effective KSM Strategies in Pharma Personalized NSCLC Treatments Focus on EGFR Inhibitor Selection and Patient-Specific Factors FDA Grants Fast Track Designation to Teva’s TEV-53408 for Celiac Disease Treatment

Author

Mark Chiang